Recombinant Cynomolgus/Rhesus CSF1 protein(Met1-Asn190), hFc-tagged

• Cat.No.: CSF1-340C
• Product Overview: Recombinant Cynomolgus / Rhesus CSF1 (XP_005542489.1) (Met1-Asn190) was expressed in HEK293 with the Fc region of Human IgG1 at the C-terminus. Cynomolgus and Rhesus CSF1 sequences are identical.

Specification

• Source: HEK293
• Species: Cynomolgus/Rhesus
• Tag: C-hFc
• Protein length: Met1-Asn190
• Form: Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization.
• Bio-activity: Measured in a cell proliferation assay using M-NFS-60 mouse myelogenous leukemia lymphoblast cell. The ED50 for this effect is typically 25-140 ng/mL.
• Molecular Mass: The recombinant cynomolgus / rhesus CSF1 consists of 396 amino acids and predicts a molecular mass of 45.1 kDa.
• Endotoxin: < 1.0 EU per μg protein as determined by the LAL method.
• Purity: > 95 % as determined by SDS-PAGE
• Storage: Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
• Reconstitution: It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents.

Reviews

10/30/2017

The CSF1 protein is renowned for its exceptional quality and reliability, making it an ideal choice to fulfill my experimental requirements.

03/10/2017

With its high purity and stability, this protein ensures dependable and accurate results, which are crucial for the success of my research endeavors.

06/09/2016

Whether it is for investigating cellular pathways, studying protein functions, or exploring signaling cascades, the CSF1 protein offers unparalleled versatility and performance.

Q&As

How does CSF1 affect cancer progression?

CSF1 is implicated in tumor-associated macrophages, influencing tumor growth, invasion, and the tumor microenvironment.

What are the potential side effects of CSF1 therapy?

Side effects may include immune-related adverse events, inflammation, and alterations in white blood cell counts.

Can CSF1 therapy be combined with other treatments?

Yes, there is ongoing research on combining CSF1-targeted therapies with other immunotherapies or conventional treatments to enhance efficacy.

What are the challenges in developing CSF1-based therapies?

Challenges include maintaining the balance of immune responses, potential off-target effects, and variability in patient responses.

In what ways is CSF1 being researched for neurological disorders?

Studies are exploring its role in neuroinflammation, neuroprotection, and potential therapeutic interventions for conditions like Alzheimer's disease.